| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | -45.13% | -94.99% | -511.46% | -200.30% | -418.20% | -572.69% | -119.89% | -305.80% | -326.70% |
| EBITDA Margin | -43.98% | -93.24% | -505.35% | -195.51% | -407.92% | -558.17% | -116.26% | -300.87% | -322.12% |
| Net Margin | -30.77% | -75.51% | -467.90% | -214.99% | -408.99% | -547.35% | -163.56% | -289.59% | -317.32% |
| Current Ratio | 4.92 | 4.64 | 4.98 | 4.20 | 5.93 | 14.32 | 8.86 | 8.52 | 3.67 |
| Quick Ratio | 4.92 | 4.64 | 4.98 | 4.20 | 5.93 | 14.32 | 8.86 | 8.52 | 3.67 |
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | -0.01 |
| ROE | -18.62% | -35.41% | -55.65% | -50.01% | -24.43% | -18.58% | -31.01% | -30.35% | 39.27% |
| ROA | -11.26% | -18.22% | -28.15% | -22.27% | -12.08% | -16.63% | -23.30% | -20.82% | -35.98% |
| Asset Turnover | 0.37 | 0.24 | 0.06 | 0.10 | 0.03 | 0.03 | 0.14 | 0.07 | 0.11 |
| Book Value / Share | 6.12 | 7.81 | 11.89 | 10.62 | 15.63 | 16.26 | 6.89 | 14.50 | -32.27 |
Arvinas Inc. is a clinical-stage biotechnology company focused on discovering, developing, and advancing proteolysis targeting chimeras (PROTAC) targeted protein degraders. These innovative therapies harness the body's natural protein disposal system to selectively degrade and remove disease-causing proteins, enabling treatment of previously undruggable targets in oncology and neurodegenerative disorders. Its pipeline features investigational candidates such as vepdegestrant for ESR1-mutated, ER-positive/HER2-negative advanced breast cancer; bavdegalutamide (ARV-110) and ARV-766 for metastatic castration-resistant prostate cancer targeting the androgen receptor; ARV-471 for metastatic ER-positive/HER2-negative breast cancer; ARV-102 for Parkinson's disease; and ARV-806 for KRAS G12D-mutated cancers including pancreatic, colorectal, and lung types. Arvinas Inc. generates revenue through strategic partnerships, licensing agreements, and clinical milestones, positioning it as a leader in targeted protein degradation within the biotechnology sector. Founded in 2013 and headquartered in New Haven, Connecticut, the company advances multiple programs through clinical trials and regulatory submissions.